Pathophysiologic biomarkers related to AD lesions include amyloid positron emission tomography (PET), cerebrospinal fluid (CSF) concentrations of amyloid and tau proteins, and plasma concentrations of amyloid, tau, and other protein biomarkers. This evidence concerns the gene MAPT and Alzheimer disease.